as described in any prospectus supplement or any free writing prospectus in connection with a specific offering, we intend to
use the net proceeds from the sale of the securities offered under this prospectus for working capital and general corporate purposes,
including continued development of its first assay, DetermaVu™, a confirmatory lung cancer diagnostic. We may also use a
portion of the net proceeds to acquire or in-license additional product candidates or complementary assets or businesses; however,
we currently have no agreements, commitments or understandings to complete any such transaction.
have not yet identified the amounts we intend to spend on these areas or the timing of the expenditures, which will be based on
many factors. Accordingly, our management will have broad discretion regarding the use of, and investors will be relying on the
judgment of our management regarding the application of, the net proceeds from the sale of the securities offered under this prospectus.
Pending these uses, we intend to invest the net proceeds in short-term, interest bearing, investment-grade securities. We cannot
predict whether these investments will yield a favorable return.
OF EARNINGS TO FIXED CHARGES AND PREFERRED STOCK DIVIDENDS
following table sets forth, for the periods presented, our ratio of earnings to fixed charges and our ratio of earnings to combined
fixed charges and preferred stock dividends. We had no shares of preferred stock outstanding and no preferred stock dividend requirements
during these periods, so these ratios are the same. For purposes of computing these ratios, “earnings” consist of
our net loss plus our fixed charges, and “fixed charges” consist of an estimate of the interest within rental expense,
the interest payments on our loan payable to Silicon Valley Bank, amortization of debt discount on the loan payable to Silicon
Valley Bank, and the interest payments on our equipment leases.
each of the periods presented, earnings were insufficient to cover fixed charges and preferred stock dividends, and the extent
of such deficiencies in each period is shown below.
Ended December 31,|| ||
|| || |
||2017 || ||
of earnings to fixed charges and preferred stock dividends||
of earnings available to cover combined fixed charges and preferred stock dividends||